Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a
certain kind of light. When the drug is active, tumor cells are killed.
PURPOSE: This randomized phase I trial is studying the side effects and best dose of
photodynamic therapy in treating patients with premalignant or early stage head and neck
tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania